GlassScriptPhysician profile
Vandana Vedula
NPI 1922059153
$1,547.95
in general payments reported to CMS, 2019-2025
27 companies · $54.58 in 2025
The $54.58 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2020: $199 · 2021: $158 · 2022: $429 · 2023: $332 · 2024: $28.81 · 2025: $54.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $415.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $322.17 | 2019-2023 | Rinvoq, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $157.29 | 2019-2020 | |
| Janssen Biotech, INC. | $140.73 | 2019-2025 | Imbruvica, Darzalex, Tremfya |
| Rigel Pharmaceuticals, INC. | $98.00 | 2022 | |
| Tactile Systems Technology INC | $96.19 | 2022-2024 | Flexitouch Plus, Entre Plus |
| Incyte Corporation | $85.80 | 2021-2022 | |
| Seagen INC. | $73.07 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $57.49 | 2022-2023 | Yonsa, Odomzo |
| Merck Sharp & Dohme LLC | $50.17 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $49.99 | 2022 | |
| Genzyme Corporation | $37.06 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $36.88 | 2023 | Dupixent |
| Jazz Pharmaceuticals INC. | $35.33 | 2021 | |
| Celltrion USA INC. | $33.67 | 2023 | Vegzelma |
| Sobi, INC | $33.48 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $31.96 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.29 | 2020-2021 | |
| Pharmacosmos Therapeutics INC. | $28.02 | 2023 | Monoferric |
| Pfizer INC. | $25.17 | 2019-2020 | |
| Astellas Pharma US INC | $25.10 | 2025 | Xtandi |
| Gilead Sciences, INC. | $24.22 | 2019 | |
| Lilly USA, LLC | $16.47 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.18 | 2021 | |
| Eisai INC. | $13.80 | 2019 | |
| Intercept Pharmaceuticals, INC. | $11.55 | 2019 | |
| Daiichi Sankyo INC. | $10.87 | 2019 | |
| Qol Medical, LLC | $8.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vandana Vedula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.